Beharier Ofer, Kahn Joy, Shusterman Eden, Sheiner Eyal
Department of Obstetrics and Gynecology, Faculty of Health Sciences, Soroka University Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
J Matern Fetal Neonatal Med. 2012 Sep;25(9):1523-8. doi: 10.3109/14767058.2012.664200. Epub 2012 Mar 13.
Birth asphyxia results in a significant percentage of neonatal morbidity and mortality. A key factor in the management of this complication is the early and accurate detection of brain damage following asphyxia. Currently, reliable tools for such diagnosis are absent. Extensive research has focused on biomarkers in an attempt to solve this matter. Recent data marked serum and urine elevation of the S100B protein as an established peripheral biomarker for detection of brain injury including traumatic head injuries and brain damage following cardiac arrest and stroke. In the past decade, a substantial number of studies illustrated the potential use of S100B testing in order to detect brain damage in asphyxiated newborns. This review summarizes the available data regarding the use of S100B as a biomarker of brain damage following birth asphyxia.
出生窒息导致相当比例的新生儿发病和死亡。管理这一并发症的关键因素是早期准确检测窒息后的脑损伤。目前，缺乏用于此类诊断的可靠工具。广泛的研究集中在生物标志物上，试图解决这一问题。最近的数据表明，血清和尿液中S100B蛋白升高是一种已确立的外周生物标志物，用于检测脑损伤，包括创伤性头部损伤、心脏骤停和中风后的脑损伤。在过去十年中，大量研究表明S100B检测在检测窒息新生儿脑损伤方面的潜在用途。本综述总结了关于使用S100B作为出生窒息后脑损伤生物标志物的现有数据。
